[1] |
中国卒中学会. 中国卒中后认知障碍防治研究专家共识[J]. 中国卒中杂志, 2020, 15(2): 158. doi: 10.3969/j.issn.1673-5765.2020.02.010 |
[2] |
王陇德, 王金环, 彭斌, 等. 中国脑卒中防治报告2016概要[J]. 中国脑血管病杂志, 2017, 14(4): 217. doi: 10.3969/j.issn.1672-5921.2017.04.010 |
[3] |
中国卒中学会. 卒中后认知障碍管理专家委员会[J]. 中国卒中杂志, 2017, 12(6): 519. doi: 10.3969/j.issn.1673-5765.2017.06.011 |
[4] |
DOUIRI A, RUDD AG, WOLFE, CD. Prevalence of poststroke cognitive impairment: South London stroke register 1995-2010[J]. Stroke, 2013, 44(1): 138. doi: 10.1161/STROKEAHA.112.670844 |
[5] |
喻才元, 何艳婷, 周宇. 神经丝轻链多肽与疾病的关系研究进展[J]. 医学综述, 2015, 21(11): 1959. doi: 10.3969/j.issn.1006-2084.2015.11.015 |
[6] |
ZETTERBERG H, SKILLEÄCK T, MATTSSON N, et al. Association of cerebrospinal fluid neurofilament light concentration with alzheimer disease progression[J]. JAMA Neurol, 2016, 73(1): 60. doi: 10.1001/jamaneurol.2015.3037 |
[7] |
SKILLEÄCK T, FARAHMAND B, BARTLETT JW, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival[J]. Neurology, 2014, 83(21): 1945. doi: 10.1212/WNL.0000000000001015 |
[8] |
SKILLEÄCK T, MATTSSON N, BLENNOWlK, et al. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2017, 18(5/6): 397. |
[9] |
ROSENGREN LE, KARLSSON JE, KARLSSON JO, et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF[J]. J Neurochem, 1996, 65(5): 2013. |
[10] |
PREISCHE O, SCHULTZ SA, APEL A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease[J]. J Nat Med, 2019, 25(2): 277. doi: 10.1038/s41591-018-0304-3 |
[11] |
HJALMARSSON C, BJERKE M, ANDERSSON B, et al. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke[J]. J Cent Nerv Syst Dis, 2014, 6: 51. |
[12] |
PETZOLD A, MICHEL P, STOCK M, et al. Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcome[J]. J Stroke Cerebrovasc Dis, 2008, 17(4): 196. doi: 10.1016/j.jstrokecerebrovasdis.2008.02.002 |
[13] |
PUJOL-CALDER NF, PORTELIUS E, ZETTERBERG H, et al. Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke[J]. Neurosci Lett, 2019, 698: 58. doi: 10.1016/j.neulet.2018.12.042 |
[14] |
KALARIA RN, AKINYEMI R, IHARA M. Stroke injury, cognitive impairment and vascular dementia[J]. Biochimica Et Biophysica Acta, 2016, 1862(5): 915. doi: 10.1016/j.bbadis.2016.01.015 |
[15] |
SHIM H. Vascular cognitive impairment and post-stroke cognitive deficits[J]. Curr Neurol Neurosci Rep, 2014, 14(1): 418. doi: 10.1007/s11910-013-0418-4 |
[16] |
GATTRINGER T, PIRPAMER L, HOFER E, et al. Serum neurofilament light is sensitive to active cerebral small vessel disease[J]. Neurology, 2017, 89(20): 2108. doi: 10.1212/WNL.0000000000004645 |
[17] |
TRAENKA C, DISANTO G, SEIFFGE DJ, et al. Serum neurofilament light chain levels are associated with clinical characteristics and outcome in patients with cervical artery dissection[J]. Cerebrovasc Dis, 2015(5/6), 40: 222. doi: 10.1159/000440774 |
[18] |
BERGMAN J, DRING A, ZETTERBERG H. et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matterinjury in MS[J]. Neurol Neuroimmunol Neuroinflamm, 2016, 3(5): e271. doi: 10.1212/NXI.0000000000000271 |
[19] |
KUHLE J, GAIOTTINO J, LEPPERT D, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome[J]. Neurol Neurosurg Psychiatry, 2015, 86(3): 273. doi: 10.1136/jnnp-2013-307454 |
[20] |
BORDET R, IHL R, KORCZYN AD. Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report[J]. BMC Med, 2017, 15(1): 2. doi: 10.1186/s12916-016-0762-8 |
[21] |
LEYS D, HENON H, MACKOWIA-CORDOLIANI MA, et al. Poststroke dementia[J]. Lancet Neurol, 2005, 4(11): 752. doi: 10.1016/S1474-4422(05)70221-0 |
[22] |
MEETER LH, DOPPER EG, JISKOOT LC, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia[J]. Ann Clin Transl Neurol, 2016, 3(8): 623. doi: 10.1002/acn3.325 |
[23] |
PIJNENBURG YA, VERWEY NA, VAN DER FLIER WM, et al. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes[J]. Alzheimers Dement (Amst. ), 2015, 1(4): 505. doi: 10.1016/j.dadm.2015.11.001 |
[24] |
MATTSSON N, ANDREASSON U, ZETTERBERG H, et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease[J]. JAMA Neurol, 2017, 74(5): 557. doi: 10.1001/jamaneurol.2016.6117 |
[25] |
WESTON PSJ, POOLE T, RYAN NS, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration[J]. Neurology, 2017, 89(21): 2167. doi: 10.1212/WNL.0000000000004667 |
[26] |
SJOGREN M, BLOMBERG M, JONSSON M, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes[J]. J Neurosci Res, 2001, 66(3): 510. doi: 10.1002/jnr.1242 |
[27] |
IDLAND AV, SALA-LLONCH R, BORZA T, et al. CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults[J]. Neurobiol Aging, 2017, 49: 138. doi: 10.1016/j.neurobiolaging.2016.09.012 |